

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/544,145 |
| Sheet | 1 | of | 7 | Filing Date | August 2, 2005 |
| | | | | First Named Inventor | Shyam S. Mohapatra |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | Scott D. Long |
| | | | | Attorney Docket Number | USF.T192XC1 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| U1 | US-2006-0276382-A1 | 12-07-2006 | Mohapatra | All | |
| U2 | US-2002/0044919 | 04-18-2002 | Yu | All | |
| U3 | US-2005/0025742 A1 | 02-03-2005 | Engler <i>et al.</i> | All | |
| U4 | US-2005/0054052 A1 | 03-10-2005 | Carr <i>et al.</i> | All | |
| U5 | US-2005/0054053 A1 | 03-10-2005 | Aguinaldo <i>et al.</i> | All | |
| U6 | US-2005/0084478 A1 | 04-21-2005 | Liu <i>et al.</i> | All | |
| U7 | US-2005/0272650 | 12-08-2005 | Mohapatra | All | |
| U8 | US-4,414,150 | 11-08-1983 | Goeddel | All | |
| U9 | US-4,456,748 | 06-26-1984 | Goeddel | All | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| F1 | | WO 01/22970 A1 | 04-05-2001 | The Cleveland Clinic Foundation | All | |
| F2 | | WO 2003/074561 A1 | 09-12-2003 | Univ. of South Florida | All | |
| F3 | | WO 03/089003 A1 | 10-30-2003 | Imperial College Innovations Ltd | All | |
| F4 | | WO 2004/074314 A2 | 09-02-2004 | Univ. of South Florida | All | |
| F5 | | WO 2004/022003 A3 | 03-18-2004 | Univ. of South Florida | All | |
| F6 | | WO 2005/094420 A2 | 10-13-2005 | Univ. of South Florida | All | |
| F7 | | WO 90/09780 A1 | 09-07-1990 | Danbiosyst UK Lmtd. | All | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and maintaining the information and transmitting it to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/544,145 |
| Sheet | 2 | of | 7 | Filing Date | August 2, 2005 |
| | | | | First Named Inventor | Shyam S. Mohapatra |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | Scott D. Long |
| | | | | Attorney Docket Number | USF T192XC1 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| | U10 | US-4,678,751 | 07-07-1987 | Goeddel | All |
| | U11 | US-4,695,623 | 09-22-1987 | Stabinsky | All |
| | U12 | US-4,897,471 | 01-30-1990 | Stabinsky | All |
| | U13 | US-5,766,864 | 06-16-1998 | Uno <i>et al.</i> | All |
| | U14 | US-5,770,191 | 06-23-1998 | Johnson <i>et al.</i> | All |
| | U15 | US-5,831,062 | 11-03-1998 | Taylor | All |
| | U16 | US-5,853,755 | 12-29-1998 | Foldvari | All |
| | U17 | US-6,120,762 | 09-19-2000 | Johnson <i>et al.</i> | All |
| | U18 | US-7,354,908 | 04-08-2008 | Mohapatra <i>et al.</i> | All |
| | U19 | US-7,118,888 | 10-10-2006 | Mohapatra <i>et al.</i> | All |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | * ¹ |
|--------------------|-----------------------|--|--------------------------------|--|--|----------------|
| | F8 | WO 98/02457 A1 | 01-22-1998 | Connaught Lab. Lmtd. | All | |
| | F9 | | | | | |
| | F10 | | | | | |
| | F11 | | | | | |
| | F12 | | | | | |
| | F13 | | | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

7

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/544,145 |
| Filing Date | August 2, 2005 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1633 |
| Examiner Name | Scott D. Long |
| Attorney Docket Number | USF T192XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | R1 | AGNIHOTRI, S.A. et al. "Recent advances on chitosan-based micro- and nanoparticles in drug delivery" <i>J Control Release</i> , 2004 Nov 5, 100(1):5-28. | |
| | R2 | AGRAWAL, S. and KANDIMALLA, E.R. "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Mol. Med. Today</i> , 2000, 6:72-81 | |
| | R3 | ANTONIOU, K.M. et al. "Interferons and their application in the diseases of the lung" <i>Chest</i> , 2003, 123:209-216. | |
| | R4 | ARAL, C. and AKBUGA, J. "Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA/poly(L-lysine) complexes" <i>J Pharm Pharm Sci.</i> , 2003 Sep-Dec, pp. 321-6, Vol. 6, No. 3. | |
| | R5 | BENAVENTE, J. et al. "Indiscriminate Degradation of RNAs in Interferon-Treated, Vaccinia Virus-Infected Mouse L Cells" <i>J. Virology</i> , 1984, pp. 866-871, Vol. 51, No. 3. | |
| | R6 | BISBAL, C. et al. "Cloning and Characterization of a RNase L Inhibitor" <i>J. Biol. Chem.</i> , 1995, pp. 13308-13317, Vol. 270, No. 22. | |
| | R7 | BRANCH, A. "A good antisense molecule is hard to find" <i>Trends in Biochem. Sci.</i> , 1998, 23:45-50. | |
| | R8 | CEVC, G. et al. "Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin" <i>Biochim. Biophys. Acta</i> , 1998, 1368:201-215. | |
| | R9 | CHEN, J.H. "Application of cationic polymer vector for gene delivery systems" <i>Yao Xue Xue Bao</i> , 2003 Apr, 38(4):316-20, abstract. | |
| | R10 | CHEN, W.R. "Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant" <i>Photochem Photobiol.</i> , 2005 Jan-Feb, 81(1):190-5, abstract. | |
| | R11 | CHIRILA, T. et al. "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides" <i>Biomaterials</i> , 2002, 23:321-342. | |
| | R12 | COCCIA, E.M. et al. "Cells resistant to interferon-β respond to interferon-γ via the Stat1-IRF-1 pathway" <i>Virology</i> , 1995, 211:113-122. | |
| | R13 | COHEN, A.D. et al. "Modulating the immune response to genetic immunization" <i>FASEB J.</i> , 1998, pp. 1611-1626, Vol. 12. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

7

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/544,145 |
| Filing Date | August 2, 2005 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1633 |
| Examiner Name | Scott D. Long |
| Attorney Docket Number | USF.T192XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | R14 | COLLINS, P.L. <i>et al.</i> "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development" <i>PNAS USA</i> , 1995, 92:11563-11567. | |
| | R15 | CROOKE, S.T. "Basic principles of antisense therapeutics" in <i>Antisense Research and Application</i> , Ed. by Crooke, S.T., 1998, Chapter 1, pages 1-50. | |
| | R16 | DOBSON, J. "Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery" <i>Gene Therapy</i> , 2006, 13:283-287. | |
| | R17 | DOMACHOWSKIE, J. and ROSENBERG, H. "Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment" <i>Clin. Microbiol. Rev.</i> , 1999, 12:298-309. | |
| | R18 | ELLIOTT, G. and O'HARE, P. "Intercellular trafficking and protein delivery by a herpesvirus structural protein" <i>Cell</i> , 1997, 88:223-233. | |
| | R19 | ENGLEBIENNE, P. "RNase L in health and disease: What did we learn recently?" <i>J. Chronic Fatigue Syndrome</i> , 2003, 11(2):97-109. | |
| | R20 | FOLDVARI, M. and MORELAND, A. "Clinical observations with topical liposome-encapsulated interferon alpha for the treatment of genital papillomavirus infections" <i>J. Liposome Res.</i> , 1997, 7:115-125. | |
| | R21 | FOLDVARI, M. <i>et al.</i> "Liposome encapsulated prostaglandin E ₁ in erectile dysfunction: Correlation between in vitro delivery through foreskin and efficacy in patients" <i>Urology</i> , 1998, 52(5):838-843. | |
| | R22 | GOSWAMI, B.B. and O.K. SHARMA "Degradation of rRNA in Interferon-treated Vaccinia Virus-infected Cells" <i>J. Biol. Chem.</i> , 1984, 259(3):1371-1374. | |
| | R23 | GUANG LIU, W. and DE YAO, K. "Chitosan and its derivatives--a promising non-viral vector for gene transfection" <i>J Control Release</i> , 2002 Sep 18, 83(1):1-11. | |
| | R24 | GUTTERMAN, J.U. "Cytokine therapeutics: Lessons from interferon α " <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91:1198-1205. | |
| | R25 | HELLERMANN, G.R. and MOHAPATRA, S.S. "Genetic therapy: on the brink of a new future" <i>Gen Vacc & Ther</i> , 2003, 1:1. | |
| | R26 | JEONG, H.J. <i>et al.</i> "Nitric oxide production by high molecular weight water-soluble chitosan via nuclear factor-kappaB activation" <i>Int J Immunopharmacol</i> , 2000 Nov, 22(11):923-33. | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

7

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/544,145 |
| Filing Date | August 2, 2005 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1633 |
| Examiner Name | Scott D. Long |
| Attorney Docket Number | USF.T192XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | R27 | JUMMA, M. et al. "Physiochemical properties of chitosan-lipid emulsions and their stability during the autoclaving process." <i>Int'l J Pharm.</i> , 1999, 183:175-184. | |
| | R28 | KUMAR, MNV R. et al. "Nanoparticle-mediated gene delivery: state of the art" <i>Expert Opin. Biol. Ther.</i> , 2004, 4(8):1213-1224. | |
| | R29 | KIM, T.H. et al. "Efficient gene delivery by urocanic acid-modified chitosan" <i>J Control Release</i> , 2003 Dec 12, 93(3):389-402. | |
| | R30 | KIM, T.H. et al. "Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier" <i>Biomaterials</i> , 2004 Aug, 25(17):3783-92. | |
| | R31 | KINSEY, B. et al. "Non-viral gene delivery to the lungs" <i>Current Gene Therapy</i> , 2005, 5:181-194. | |
| | R32 | KOPING-HOGGARD, M. et al. "Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers" <i>Gene Ther.</i> , 2004 Oct, 11(19):1441-52. | |
| | R33 | KUMAR, M. et al. "Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy for allergic asthma" <i>Genet Vacc & Ther.</i> , 2003, 1(1):3. | |
| | R34 | LEONG, K.W. et al. "DNA-polycation nanospheres as non-viral gene delivery vehicles" <i>J. Controlled Release</i> , 1998, 53:183-193. | |
| | R35 | LI, X-L et al. "RNase L Mediates the Antiviral Effect of Interferon through a Selective Reduction in Viral RNA during Encephalomyocarditis Virus Infection" <i>J. Virology</i> , 1998, 72(4):2752-2759. | |
| | R36 | MANSOURI, S. et al. "Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy" <i>Eur J Pharm Biopharm.</i> , 2004 Jan, 57(1):1-8. | |
| | R37 | MAO, H-Q. et al. "Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency" <i>J. Controlled Release</i> , 2001, 70(3):399-421. | |
| | R38 | MATSUSE, H. et al. "Differential cytokine mRNA expression in <i>Dermatophagoides farinae</i> allergen-sensitized and respiratory syncytial virus-infected mice" <i>Microbes and Infect.</i> , 2000, 2:753-759. | |
| | R39 | MOHAPATRA, S.S. "Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus" <i>Pediatr. Infect. Dis. J.</i> , 2003, 22(2 Suppl):S100-S104. | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

7

control number

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/544,145 |
| Filing Date | August 2, 2005 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1633 |
| Examiner Name | Scott D. Long |
| Attorney Docket Number | USF T192XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | R40 | MOHAPATRA, S. Poster materials presented at International RSV Conference on June 22, 2002, Washington, D.C. (9 pages, including abstract and Figures 1-4 with captions). | |
| | R41 | MONTGOMERY, D. et al. "DNA vaccines" <i>Pharmacol. Ther.</i> , 1997, 74:195-205. | |
| | R42 | OPALINSKA, J.B. and GEWIRTZ, A. "Nucleic-acid therapeutics: Basic principles and recent applications" <i>Nature Rev.</i> , 2002, 1:503-514. | |
| | R43 | OPDENAKKER, G. et al. "Interaction of interferon with other cytokines" <i>Experientia</i> , 1989, 45:513-520. | |
| | R44 | PARK, S-Y. et al. "IFN- γ enhances TRAIL-induced apoptosis through IRF-1" <i>Eur. J. Biochem.</i> , 2004, 271(21):4222-4228. | |
| | R45 | PAYNE, L. et al. "Particle-mediated DNA vaccination of mice, monkeys and men: Looking beyond the dogma" <i>Curr. Opin. Mol. Therapeu.</i> , 2002, 4:459-466. | |
| | R46 | PENG, J. et al. "Influence of anions on the formation and properties of chitosan-DNA nanoparticles" <i>J Nanosci Nanotechnol.</i> , 2005 May, 5(5):713-7, abstract. | |
| | R47 | PERACCHI, A. "Prospects for antiviral ribozymes and deoxyribozymes" <i>Rev. Med. Virol.</i> , 2004, 14:47-64. | |
| | R48 | POOGA, M. et al. "Cell penetration by transportan" <i>The FASEB J.</i> , 1998, 12:67-77. | |
| | R49 | POUTON, C. and SEYMOUR, L. "Key issues in non-viral gene delivery" <i>Adv. Drug Deliv. Rev.</i> , 2001, 46:187-203. | |
| | R50 | RAVI KUMAR, M. et al. "Nanoparticle-mediated gene delivery: state of the art" <i>Expert Opin Biol Ther.</i> , 2004 Aug, 4(8):1213-24, abstract. | |
| | R51 | READ, M. et al. "Barriers to gene delivery using synthetic vectors" <i>Adv. in Genetics</i> , 2005, 53:19-46. | |
| | R52 | REIS, L.F.L. et al. "Critical role of a common transcription factor, IRF-1, in the regulation of IFN- β and IFN-inducible genes" <i>The EMBO J.</i> , 1992, 11(1):185-193. | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

7

Complete if Known

| | |
|-------------------------------|--------------------|
| Application Number | 10/544,145 |
| Filing Date | August 2, 2005 |
| First Named Inventor | Shyam S. Mohapatra |
| Group Art Unit | 1633 |
| Examiner Name | Scott D. Long |
| Attorney Docket Number | USF T192XC1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | R53 | ROY, K. et al. "Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy" <i>Nat Med</i> , 1999, 5:387-391. | |
| | R54 | SETHI, S.K. et al. "Interferon-gamma (IFN- γ) down-regulates the rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) on human airway epithelial cells" <i>Clin. Exp. Immunol.</i> , 1997, 110:362-369 | |
| | R55 | SHIBATA, Y. et al. "Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice" <i>Infect Immun.</i> , 1997 May, 65(5):1734-41. | |
| | R56 | SHORT, S.M. et al. "Percutaneous absorption of biologically-active interferon-gamma in a human skin graft-nude mouse model" <i>Pharm. Res.</i> , 1996, 13:1020-1027. | |
| | R57 | SILVERMAN, R.H. "Implications for RNase L in prostate cancer biology" <i>Biochemistry</i> , 2003, 42(7):1805-1812. | |
| | R58 | SIMMONS, C.P. et al. "Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8 $^{+}$ T cell responses" <i>J. Immun.</i> , 2001, 166:1105-1113. | |
| | R59 | WAN, L.Q. et al. "Study of the uptake of chitosan oligosaccharide nanoparticles by A549 cells" <i>Yao Xue Xue Bao</i> , 2004 Mar, 39(3):227-31, abstract. | |
| | R60 | WRIGHT, P. et al. "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy" <i>J. Infect. Dis.</i> , 2000, 182:1331-1342. | |
| | R61 | XIU, Q. et al. "Effect of intratracheally administered IL-12 recombinant adenovirus on ovalbumin induced bronchial hyperresponsiveness in mouse model" <i>Chin. J. Tuberc. Respir. Dis.</i> , 2001, 24:298-301. | |
| | R62 | YOO, H.S. et al. "Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery" <i>J Control Release</i> , 2005 Mar 2, 103(1):235-43; <i>Publ 2005 Jan 15</i> . | |
| | R63 | ZHU, Z. et al. "Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation" <i>Science</i> , 2004, 304:1678-1682. | |
| | R64 | ZOON, K.C. "Human interferons: Structure and function" <i>Interferon</i> , 1987, 9:1-12. | |
| | R65 | Copy of European Patent Office Summons to attend oral proceedings pursuant to Rule 115(1) EPC, dated October 22, 2008, for corresponding EPO application no. 04711150.5. | |

| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|
| | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.